drugset
drugset / Trial / NCT04622046

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

NCT04622046 ↗

Phase 3 Completed 25 enrolled Alexion Pharmaceuticals, Inc. Eidos Therapeutics, a BridgeBio company · collab
NaSingle-groupOpen-labelTreatment

Summary

This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.

Timeline

Start
2020-11-13
Primary completion
2023-11-08
Completion
2025-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoramidis Unknown 800 mg Oral

Indications

amyloidosis